- > Media & Investors
- > Media Relations
- > Press Releases
- > Daiichi Sankyo Announces Participation in the Global Initiative, Access Accelerated
For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: George Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Daiichi Sankyo Announces Participation in the Global Initiative, Access Accelerated
Tokyo, Japan (January 18, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) has announced that it is participating in Access Accelerated, a global initiative launched at the World Economic Forum in Davos, Switzerland. Access Accelerated consists of 22 Japanese, American and European biopharmaceutical companies including Daiichi Sankyo, and aims to improve non-communicable disease (NCD) prevention, diagnostics and treatment in low and lower-middle income countries in partnership with the World Bank Group and the Union for International Cancer Control.
Nearly 80 percent of NCD-related deaths occur in low and lower-middle income countries, and measures are urgently needed to address NCDs including cancers, cardiovascular diseases, chronic respiratory diseases and diabetes. Access Accelerated will contribute towards achieving the reduction of premature mortality from NCDs by one third by 2030 through prevention and treatment and promoting mental health and well-being, a part of the Sustainable Development Goals set by the United Nations in 2015.
By providing mobile healthcare field clinics, cultivating healthcare workers and educating local residents about healthcare and hygiene, Daiichi Sankyo has already implemented a number of measures to improve access to healthcare in areas lacking sufficient medical infrastructure. In addition, cancer is an area with particularly high levels of unmet needs even among NCDs. Consequently, in 2016 Daiichi Sankyo set out a vision of becoming a “Global Pharma Innovator with a Competitive Advantage in Oncology,” and the company is leveraging its world-class, innovative science to push beyond traditional thinking in order to create meaningful treatments for patients with cancer.
With its participation in Access Accelerated, Daiichi Sankyo intends to further expand its efforts to improve access to healthcare for people around the world.